SELF-INTRODUCTION：

Hailiang Hu, PhD, is a tenure-track Associate Professor in the School of Medicine at Southern University of Science and Technology. Dr. Hu received his BS degree in Chemistry from Nankai University in 1995 and PhD degree in Biochemistry and Molecular Biology from Shanghai Institute of Biochemistry, Chinese Academy of Sciences (CAS) in 2000.  Dr. Hu then went to UCLA to complete his postdoctoral training in Biochemistry from 2001-2007. He has received many awards during his training including Baojie Award (Proctor & Gamble) in 2000, JCCF Postdoctoral Fellowship from Jonsson Cancer Center Foundation at UCLA in 2003 and the Postdoctoral Recognition Award in Research Excellence from Molecular Biology Institute at UCLA in 2006.

Dr. Hu was then promoted to Assistant Researcher and Research Assistant Professor from 2007-2016 at UCLA and became tenure-eligible Assistant Professor in the Department of Pathology at Duke University School of Medicine from 2016-2020.  Dr. Hu has finished many research projects funded by USA national agencies (including NIH and DoD) and received several notable grant supports, including California Breast Cancer Program-IDEA Award as a young investigator and California Institute of Regenerative Medicine Tools and Technologies Award as a co-PI. Dr. Hu most recently received USA PCF (Prostate Cancer Foundation) Movember Foundation Valor Challenge Award as a key co-investigator and was invited to be a panel scientist reviewer for 2019 DoD-PCRP-IDEA award. He has published over 30 papers, including peer-reviewed research articles, invited reviews and book chapters, and hold one US and Europe patent. Some of these important research discoveries have been published in prestigious international journals such as Nature Communications, PLoS Genetics, Current Biology, PNAS, Cancer Research, Nucleic Acids Res and Mol Cancer as first author or corresponding author.

EDUCATION:

1995-2000     Ph.D. Biochemistry & Molecular Biology，Shanghai Institute Biochemistry ，Chinese Academy of Sciences, Shanghai, China

1991-1995     B.S. Chemistry,    Nankai University,   Tianjin, China,

WOKRING EXPERIENCE:

2020-        Associate Professor, Southern University of Science and Technology

2016-2020     Assistant Professor, Department of Pathology, Duke University

2012-2016     Research Assistant Professor, Dept. of Pathology & Lab Medicine, UCLA School of Medicine

2007-2012     Assistant Researcher, Dept. of Pathology & Lab Medicine, UCLA School of Medicine

2001-2007     Postdoctoral Fellow, Dept. of Biological Chemistry ,UCLA School of Medicine

HONORS AND AWARDS:

2018           Movember Foundation PCF Valor Challenge Award, Prostate Cancer Foundation (PCF)

2011           California Breast Cancer Program-IDEA award (Young Investigator)

2006           Postdoctoral Recognition Award in Research Excellence, Dept. Of

Chemistry & Biochemistry and Molecular Biology Institute at UCLA

2003           JCCF Postdoctoral Fellowship, Jonsson Cancer Center Foundation (JCCF) at UCLA

2000           Baojie Award, Proctor and Gamble (Sponsor), Chinese Academy of Sciences

2000           Di’ao Award, Di’ao Limited Inc. (Sponsor), Chinese Academy of Sciences

1995           Wang Kechang Award, Nankai University

Research:

1）DNA repair, tumor metabolism and targeted therapy. We will focus on the molecular mechanisms of DNA repair and DNA damage-induced tumor metabolism reprogramming in tumor progression and therapeutic resistance with a long-term goal to develop new targeted therapies for therapy-resistant genitourinary (GU) cancers.

2）Therapy resistance and small cell neuroendocrine development of prostate cancer. We will focus on the molecular and cellular mechanisms that mediate the castration resistance development of prostate cancer and the treatment-induced small cell neuroendocrine carcinoma trans-differentiation with the goal to identify new therapeutic targets for these lethal advanced prostate cancers.

3）Non-coding RNA in tumor initiation, progression and metastasis. We will focus on DNA damage-related ncRNAs (microRNA or lncRNA) and their roles in DNA damage response and DNA damage-induced cellular metabolism alterations with a long-term goal to identify ncRNAs as prognostic biomarkers for tumors with radio/chemotherapy or as radiosensitizer/ mitigators for tumor radio/chemotherapy.

4）iPSCs and neurodegeneration disorders. We will use our established patient-derived iPSC (induced pluripotent stem cells) to study the molecular and cellular mechanisms of pathobiology of a neurodegeneration disease (Ataxia-Telangiectasia) and develop mutation- targeted therapy for these neurodegeneration diseases, as well as develop new clinical diagnostic ways for DNA repair deficiency-caused rare genetic diseases.

MANUSCRIPT REVIEWER AND EDITOR：

2019   Guest editor   Frontier in Pharmacology

2007-  ad hoc reviewer

Oncotarget ，Neoplasia ，Clinical Cancer Research，International Journal of Radiation Oncology, Biology, Physics ， Clinical Immunology， Molecular Oncology ， Journal of Molecular Cell Biology ，Cell Cycle， Human Molecular Genetics ，PLoS One ，Cell Death and Differentiation ，Oncogene ，Gene ，DNA Repair ，Bioinformatics & Biology Insights ，BMC Molecular Biology，Cell Proliferation

PUBLICATIONS：(Representative publications with first author or corresponding author)

1. Xu L, Yin Y, Chang Y, Li Y, Chen X, Liu J, Beasley J, McCaw P, Young S, Groth J, Wang Q, Locasale J, He Y, George D, Liang C, Hu H* and Huang J* Isoform switch of glutaminase drives therapeutic resistance and disease progression of prostate cancer. Proc. Natl. Acad. Sci. USA 2020 under revision (*corresponding author). (IF=9.412)

2. Yin Y, Xu L, Chang Y, Zeng T, Chen X, Wang A, Groth J, Foo WC, Liang C*, Hu H* & Huang J * N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. Molecular Cancer. 2019; 18(1):11. PMID: 30657058, PMCID: PMC6337850 (* corresponding author) (IF=15.302)

3. Xu L, Ma E, Zeng T, Zhao Y, Tao Y, Chen X, Groth J, Liang C*, Hu H* and Huang J* ATM deficiency promotes progression of castration resistant prostate cancer by enhancing Warburg effect. Endocrine-related Cancer. 2019; 26(1): 59-71 (*corresponding author) (IF=4.800)

4. Martin NT, Nakamura K, Davies R, Nahas SA, Brown C, Tunuguntla R, Gatti RA, Hu H* ATM-dependent MiR-335 targets CtIP and modulates the DNA damage response. PLoS Genet. 2013; 9(5):e1003505. PubMed PMID: 23696749, PMCID: PMC3656122 (*Corresponding author) (IF=5.174)

5. Lee P, Martin NT, Nakamura K, Azghadi S, Amiri M, Ben-David U, Perlman S, Gatti RA, Hu H*, Lowry WE*. SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs. Nature Communications. 2013; 4:1824. PubMed PMID: 23652012 (*corresponding author) (IF=12.121)

6. Hu H*, Gatti RA*. MicroRNAs: new players in the DNA damage response. J. Mol. Cell Biol. 2011; 3(3):151-8. PubMed PMID: 21183529, PMCID: PMC3104011 (* Co-corresponding author) (IF=4.000)

7. Hu H*, Du L, Nagabayashi G, Seeger RC, Gatti RA*. ATM is down-regulated by N-Myc-regulated microRNA-421. Proc. Natl. Acad. Sci. USA. 2010; 107(4):1506-11. PubMed PMID: 20080624, PMCID: PMC2824372 (* Co-corresponding author) (IF=9.412)

8. Hu H, Gatti RA. New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicals. Curr. Opin. in Allergy & Clin. Immunol. 2008; 8(6):540-6. PubMed PMID: 18978469, PMCID: PMC2686128 (IF=3.246)

9. Hu H, Milstein M, Bliss JM, Thai M, Malhotra G, Huynh LC, Colicelli J. Integration of transforming growth factor beta and RAS signaling silences a RAB5 guanine nucleotide exchange factor and enhances growth factor-directed cell migration. Mol. Cell. Biol. 2008; 28(5):1573-83. PubMed PMID: 18160707, PMCID: PMC2258770. (IF=3.611)

10. Hu H, Bliss JM, Wang Y, Colicelli J. RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration. Curr. Biol. 2005; 15(9):815-23. PubMed PMID: 15886098. (IF=9.601)

11. Hu H, Liu S, Yang Y, Chang W, Hong G. In Rhizobium leguminosarum, NodD represses its own transcription by competing with RNA polymerase for binding sites. Nucleic Acids Res. 2000; 28(14):2784-93. PubMed PMID: 10908336, PMCID: PMC102654. (IF=11.501)

Invited book chapter：

12. Hu H, MicroRNAs, DNA repair and Cancer. (2014) MicroRNA in Development and in the Progression of Cancer, Edited by Pranela Rameshwer/ Springer, Part I, 47-68.

13. Hu H*, Shareef N & Gatti RA, Assaying radiosensitivity of Ataxia-telangiectasia (2017) ATM Kinase Methods in Molecular Biology, Edited by Sergei Kozlov/Springer, Vol 1599, pp 1-11. (*corresponding author)

Patent：

14. Premature-termination-codons readthrough compounds

Inventors: Gatti RA, Du L, Hu H, Damoiseaux R, Jung ME, Ku JM, Completo G

US patent # 009598396B2

European Patent #2828249B1